• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells
This study investigated the effects of SALL2 on human ovarian carcinoma (OC) A2780 cells and the probable mechanism.
Source: BMC Cancer - December 11, 2017 Category: Cancer & Oncology Authors: Fang Miao, Xueshan Zhang, Yanning Cao, Yue Wang and Xiaoshu Zhang Tags: Research article Source Type: research

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines
Conclusions: We identified DKK1 as a possible marker of a cisplatin-refractory phenotype and as a potential novel therapeutic target to improve platinum response of NSCLC cells.
Source: BMC Cancer - September 9, 2015 Category: Cancer & Oncology Authors: Hogir SalimDali ZongPetra HåågMetka NovakBirgitta MörkRolf LewensohnLovisa LundholmKristina Viktorsson Source Type: research

The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes
Conclusions: Our data suggest that the truncated PPARα splice variant functions as an endogenous inhibitor of proliferative and pro-inflammatory genes in human cells and that its absence in mouse may explain species-specific differences in fibrate-induced hepatocarcinogenesis.
Source: BMC Cancer - June 30, 2015 Category: Cancer & Oncology Authors: Maria ThomasChristine BayhaKathrin KleinSimon MüllerThomas WeissMatthias SchwabUlrich Zanger Source Type: research

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression
Conclusions: These findings indicate that MUC16 protects EOC cells against TRAIL-induced apoptosis through multiple mechanisms including the blockade of TRAIL R2 expression and the regulation of cFLIP expression at both the transcriptional and the protein level.
Source: BMC Cancer - April 1, 2014 Category: Cancer & Oncology Authors: Isabelle MatteDenis LaneMarianne BoivinClaudine RancourtAlain Piché Source Type: research

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
Background: Ovarian cancer is now recognized as a number of distinct diseases primarily defined by histological subtype. Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from endometriosis and frequently harbor mutations in the ARID1A tumor suppressor gene. We studied the influence of histological subtype on protein expression with reverse phase protein array (RPPA) and assessed proteomic changes associated with ARID1A mutation/BAF250a expression in EC and CCC. Methods: Immunohistochemistry (IHC) for BAF250a expression was performed on 127 chemotherapy-naive ovarian carcinomas (33...
Source: BMC Cancer - February 22, 2014 Category: Cancer & Oncology Authors: Kimberly WiegandBryan HennessySamuel LeungYemin WangZhenlin JuMollianne McGahrenSteve KallogerSarah FinlaysonKatherine Stemke-HaleYiling LuFan ZhangMichael AnglesioBlake GilksGordon MillsDavid HuntsmanMark Carey Source Type: research